ANXA1 and triple-negative breast carcinoma: Furthermore, MDX-124 has also demonstrated synergy with standard chemotherapy and immune checkpoint blockade [50], as shown in preclinical triple-negative breast cancer models.​Importantly, a first-in-human clinical trial of MDX-124 is currently underway to evaluate its safety and therapeutic efficacy in patients with advanced solid tumors known to overexpress ANXA1 [51].